Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock
Bernhardt G. Zeiher, a director at Entrada Therapeutics (NASDAQ:TRDA), recently purchased 5,000 shares of the company's stock for $29,316. The transaction was made indirectly through his revocable living trust at prices ranging from $5.86 to $6.00 per share. This purchase occurs while the stock is trading at $6.31, down 41% year-to-date, and is considered undervalued according to InvestingPro analysis, with the RSI indicating oversold conditions.
Entrada Therapeutics (TRDA) director’s trust buys 5,000 common shares
A revocable living trust associated with Entrada Therapeutics director Bernhardt G. Zeiher purchased 5,000 shares of TRDA common stock. The open-market transaction occurred at a weighted average price of $5.8632 per share, with individual trades ranging from $5.86 to $6.00. Following this purchase, the trust indirectly holds 5,000 shares, and Dr. Zeiher disclaims beneficial ownership beyond pecuniary interest.
Entrada Therapeutics Reports Positive Phase 1/2 Results for ENTR-601-44 in Duchenne Muscular Dystrophy, Highlighting Best-in-Class Potential and $5B U.S. Market Opportunity 679
Entrada Therapeutics announced significant progress in its genetic medicines pipeline, especially with positive Phase 1/2 results for ENTR-601-44 in Duchenne Muscular Dystrophy, showing strong functional benefits and a favorable safety profile. The company projects a $5 billion annual U.S. market opportunity for DMD and has a cash runway into Q3 2027, supported by strategic partnerships and multiple upcoming data readouts in 2026. Entrada's differentiated EEV platform and expanding pipeline across DMD, DM1, and inherited retinal diseases position it for substantial growth and shareholder value creation.
INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC has initiated an investigation into Entrada Therapeutics, Inc. (TRDA) to determine if the company violated federal securities laws. This investigation follows a drop in Entrada's stock price after the announcement of Duchenne muscular dystrophy study results, which showed dystrophin increase below analyst expectations. Shareholders who suffered losses are encouraged to contact the law firm to discuss their legal rights.
Entrada Therapeutics (TRDA) furnishes updated corporate presentation to investors
Entrada Therapeutics (TRDA) has filed an 8-K to provide investors and analysts with an updated corporate presentation, dated May 2026. This presentation, furnished under Regulation FD, details the company's clinical-stage programs, including five in Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1), and highlights several clinical data catalysts expected in 2026, alongside their financial position. The report emphasizes the favorable safety profile and early functional benefits observed in their ELEVATE-44-201 study for DMD, as well as the de-risking of their neuromuscular portfolio.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Entrada Therapeutics, Inc. (TRDA) following a significant stock price drop. This drop occurred after the company announced "positive" Phase 1/2 clinical study results for its Duchenne Multiple Ascending Dose (MAD) treatment, which showed only a 2.36% increase in dystrophin production, deemed insufficient to be competitive. The firm encourages shareholders who purchased Entrada securities to contact them for more information regarding the potential claims.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Entrada Therapeutics, Inc. (TRDA) on behalf of investors who purchased its securities. This investigation follows a significant stock price drop after the company announced "topline data" from a clinical study, which showed only a 2.36% increase in dystrophin production—a result considered insufficient for competitive treatment against Duchenne patients. The firm encourages affected stockholders to contact them for more information regarding potential claims.
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Entrada Therapeutics, Inc. (TRDA) on behalf of investors for potential securities law violations. This follows a significant 57.3% stock drop after the company announced "positive" Phase 1/2 clinical study data for its Duchenne muscular dystrophy drug, which showed only a slight increase in a critical protein, falling short of market competitiveness. Shareholders who suffered losses are encouraged to participate in the investigation.
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Entrada Therapeutics, Inc. (TRDA) for potential securities law violations. This comes after Entrada reported "positive" Phase 1/2 clinical study data on May 7, 2026, which investors perceived as disappointing due to only a slight improvement in protein production for Duchenne patients, leading to a nearly 57.3% stock drop. The firm is now seeking investors who suffered losses to join the fraud investigation.
(TRDA) Movement Within Algorithmic Entry Frameworks
This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA) using algorithmic entry frameworks, identifying weak near and mid-term sentiment but a strong long-term outlook. It presents various trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for the stock.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Entrada Therapeutics, Inc. (NASDAQ:TRDA) following a significant drop in stock price. This decline occurred after the company announced "positive" topline data from a Phase 1/2 clinical study, which, despite the characterization, showed a dystrophin production increase significantly below what is needed for the drug to be competitive. The firm encourages affected investors to contact them to learn more about the investigation.
Entrada Therapeutics faces investigation after drug trial results disappoint, stock plunges 57%.
Entrada Therapeutics is facing an investigation by Pomerantz LLP for potential securities fraud following disappointing Phase 1/2 drug trial results. The company reported only a 2.36% increase in dystrophin production, causing its stock to fall by 57.27% on May 7, 2026, despite Entrada labeling the results as "positive." The law firm is encouraging affected investors to come forward as a class action lawsuit may be pursued.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
Pomerantz LLP is investigating potential securities fraud claims against Entrada Therapeutics, Inc. (NASDAQ: TRDA) on behalf of its investors. This investigation follows a significant drop in Entrada's stock price, which occurred after the company released "topline data" from a clinical study, showing a dystrophin production increase that was deemed insufficient to compete with other treatments. Investors are encouraged to contact Pomerantz LLP regarding their legal rights.
Entrada Therapeutics, Inc. Common Stock (TRDA) Stock Price Today & Analysis
This article provides an analysis of Entrada Therapeutics, Inc. (TRDA) stock, including its current price, fundamental financials, and company overview. It highlights key financial metrics such as market cap, price-to-sales ratio, and earnings per share, and describes the company's focus on developing new medicines for neuromuscular and ocular diseases. The article also includes a FAQ section on how to buy TRDA stock through the Gotrade app, minimum investment, dividend policy, and market hours.
Entrada Therapeutics, Inc. Shareholders Are Encouraged to
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Entrada Therapeutics, Inc. (NASDAQ: TRDA) following a sharp decline in stock price. This decline occurred after the company announced topline results from a clinical study for ENTR-601-44, which showed a lower-than-expected increase in dystrophin and plasma exposure in pediatric participants despite being described as positive overall. The investigation aims to determine if Entrada Therapeutics complied with federal securities laws.
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Entrada Therapeutics announced early positive results from the first cohort of its phase I/II ELEVATE-44-201 trial for Duchenne muscular dystrophy (DMD). The trial showed favorable safety, tolerability, and early functional improvement, with patients experiencing statistically significant gains in time-to-rise velocity despite lower-than-expected plasma exposure. The company plans an accelerated approval strategy and anticipates further clinical milestones in 2026.
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Entrada Therapeutics announced initial positive data from its ELEVATE-44-201 trial for Duchenne muscular dystrophy (DMD), showing a favorable safety profile and early functional gains in ambulatory patients. The trial met its primary objective for safety and tolerability, with treated participants demonstrating a statistically significant improvement in time-to-rise velocity. While plasma exposure was lower than anticipated, the company expects improved exon skipping and dystrophin levels in subsequent cohorts and anticipates several clinical milestones throughout 2026.
Entrada Therapeutics, Inc. - Common Stock (NQ: TRDA)
This article provides detailed stock information for Entrada Therapeutics, Inc. (TRDA), including real-time quotes, trading volumes, and performance metrics. It also compiles recent news headlines related to the company, highlighting updates on its Duchenne Muscular Dystrophy (DMD) trials, financial results, and analyst observations. Key data points such as the current stock price, 52-week range, and shares outstanding are presented.
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why
Entrada Therapeutics (NASDAQ: TRDA) stock experienced a significant sell-off after releasing Phase 1/2 clinical trial data for ENTR-601-44 in Duchenne muscular dystrophy patients. The data showed a 2.36% increase in dystrophin, falling short of analyst expectations of a 10% increase, despite showing some positive functional measurements. The stock plunged 59.48% and currently trades significantly below its moving averages, with a high RSI indicating it's in overbought territory.
Entrada Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
HC Wainwright & Co. has downgraded Entrada Therapeutics (TRDA) from a "Buy" rating to "Neutral." The article also briefly mentions Unity Software's (U.US) fourth-quarter financial results, noting a 35% revenue increase year-over-year to $609 million, exceeding consensus estimates, despite reporting a quarterly loss of 66 cents per share.
Duchenne study finds no serious side effects, better Time to Rise
Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study for ENTR-601-44 in Duchenne Muscular Dystrophy patients, showing a favorable safety profile with no serious adverse events and a statistically significant improvement in Time to Rise velocity. Despite lower-than-expected plasma exposure in pediatric participants, the company is proceeding with a higher 12 mg/kg dose in Cohort 2, expecting increased plasma AUC and higher dystrophin levels by year-end 2026. The news, however, led to a significant 57.27% decline in TRDA stock on the day of publication, possibly due to concerns about dilution or profit-taking.
Entrada Therapeutics Declines on Duchenne Muscular Dystrophy Study Data -- Update
Entrada Therapeutics (entr) experienced a decline in its stock following the release of interim data from its Phase 1 clinical trial of ENTR-601-44 for Duchenne Muscular Dystrophy (DMD). The reported data, while showing a dose-dependent increase in target engagement, did not meet anticipated levels, leading to a negative market reaction. Future full data sets are expected to be available in the second half of 2026.
Entrada Therapeutics (TRDA) Q1 Revenue Slump Tests High Growth Narratives
Entrada Therapeutics reported a significant Q1 2026 revenue slump to US$0.9 million and a US$0.95 EPS loss, contrasting sharply with previous year's figures. Despite a forecast of 49.8% annual revenue growth, the company faces persistent net losses and trades at a high 43.6x P/S ratio, indicating market optimism for future earnings that must contend with current unprofitability and stock volatility. Analysts see a large implied upside to a target of US$21.40 from the current US$6.85, but this relies heavily on future revenue growth materializing into profitability.
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
Entrada Therapeutics announced positive topline results from Cohort 1 of its ELEVATE-44-201 study for ENTR-601-44 in Duchenne Muscular Dystrophy. The study showed favorable safety and tolerability, with no serious adverse events and normal kidney function markers. Despite lower-than-expected plasma exposure in pediatric participants, the drug demonstrated a statistically significant improvement in Time to Rise velocity, alongside modest increases in dystrophin and exon skipping.
Entrada Therapeutics to report phase 1/2 trial data Thursday
Entrada Therapeutics (NASDAQ:TRDA) is set to release topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 clinical study for ENTR-601-44 on Thursday. The company's stock has recently surged by 24% and is trading near its 52-week high. Entrada Therapeutics, a biopharmaceutical company, focuses on genetic medicines for neuromuscular and inherited retinal diseases, particularly Duchenne muscular dystrophy.
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why
Entrada Therapeutics (NASDAQ: TRDA) shares crashed due to disappointing clinical trial data for ENTR-601-44 in Duchenne muscular dystrophy patients, where dystrophin protein expression increased by only 2.36% against an expected 10%. While the treatment did show a statistically significant improvement in Time to Rise velocity, the key efficacy endpoint miss led to a nearly 60% stock selloff. The company plans to release data from an increased dose cohort by year-end 2026.
Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Entrada Therapeutics, Inc. reported a significant increase in net loss for the first quarter ended March 31, 2026, reaching USD 39.72 million compared to USD 17.35 million in the prior year. This resulted in a basic and diluted loss per share from continuing operations of USD 0.95, up from USD 0.42 a year ago. The company, a clinical-stage biopharmaceutical firm, is focusing on developing RNA-based therapeutics for neuromuscular and inherited retinal diseases.
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study for ENTR-601-44, an investigational treatment for Duchenne muscular dystrophy. The study achieved its primary objective with favorable safety and tolerability, no discontinuations, and no serious adverse events. Despite lower plasma exposure in juvenile participants, ENTR-601-44 demonstrated a statistically significant improvement in Time to Rise velocity, a clinically validated functional measurement, and an increase in dystrophin and exon skipping over baseline in treated participants.
Entrada Therapeutics (NASDAQ: TRDA) posts Q1 2026 results and promising Duchenne data
Entrada Therapeutics reported Q1 2026 financial results, including a collaboration revenue of $0.9 million and a net loss of $39.7 million, while maintaining a strong cash position of $254.9 million expected to last into Q3 2027. The company also announced positive early data from Cohort 1 of its ELEVATE-44-201 study for Duchenne muscular dystrophy, showing favorable safety, increased dystrophin and exon skipping, and a statistically significant improvement in Time to Rise velocity. This clinical advancement helps offset the reduced collaboration revenue.
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study for ENTR-601-44 in Duchenne Muscular Dystrophy (DMD) patients amenable to exon 44 skipping. The study reported favorable safety and tolerability, with no serious adverse events, and a statistically significant improvement in Time to Rise velocity, a clinically validated functional measurement. The company plans to report Cohort 2 data by year-end 2026, anticipating higher dystrophin levels due to increased dosing and updated PK modeling.
Entrada Therapeutics to report phase 1/2 trial data Thursday
Entrada Therapeutics (NASDAQ:TRDA) is set to release topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday. The company's stock has recently surged by 24% and is trading near its 52-week high. An investor webcast will be held to discuss the clinical results for ENTR-601-44, which targets Duchenne muscular dystrophy.
Entrada Therapeutics to Announce Topline ENTR-601-44 DMD Trial Results on May 7, 2026
Entrada Therapeutics is set to announce topline results from the first cohort of participants in its Phase 1/2 ELEVATE-44-201 study for Duchenne Muscular Dystrophy (DMD) on May 7, 2026. The study is evaluating ENTR-601-44, an investigational therapeutic. This announcement will provide an initial assessment of the treatment's safety and efficacy in DMD patients.
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Entrada Therapeutics announced that it will release topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 clinical study for ENTR-601-44, targeting Duchenne Muscular Dystrophy, on Thursday, May 7, 2026. The company will host an investor webcast and conference call to discuss these findings. Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing genetic medicines for difficult-to-target intracellular pathways, including programs for neuromuscular and inherited retinal diseases.
Entrada Therapeutics R&D president sells $398,809 in shares
Sethuraman Natarajan, President of Research & Development at Entrada Therapeutics, Inc. (NASDAQ:TRDA), sold 25,907 shares worth approximately $398,809 on May 4, 2026. This sale was made under a Rule 10b5-1 trading plan adopted in November 2024. InvestingPro analysis suggests the stock is overvalued, and the company, valued at $530 million, is quickly burning through cash despite holding more cash than debt.
Entrada Therapeutics president & COO sells $229,953 in shares
Nathan J. Dowden, President & COO of Entrada Therapeutics (NASDAQ:TRDA), sold 15,000 shares of the company's common stock for $229,953 on May 4, 2026, after exercising options for the same number of shares. The sale was executed under a Rule 10b5-1 trading plan adopted in March 2025, and Dowden now directly holds 198,588 shares.
Entrada Therapeutics (TRDA) R&D president sells 25,907 shares under 10b5-1 plan
Entrada Therapeutics' President of Research & Development, Sethuraman Natarajan, sold 25,907 shares of common stock at a weighted average price of $15.3939 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2024. Following the sale, Natarajan directly holds 216,317 shares in the company.
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity
Entrada Therapeutics President & COO Nathan J. Dowden reported an insider transaction involving the exercise of stock options to acquire 15,000 shares at $1.74 and the subsequent sale of these shares at a weighted average price of $15.3302. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Dowden directly owns 198,588 shares and holds 49,831 exercisable stock options.
Morgan Stanley Smith Barney files TRDA Form 144; 15,000 shares sold (TRDA)
Morgan Stanley Smith Barney LLC has filed a Form 144 notice, reporting the sale of 15,000 shares of Entrada Therapeutics, Inc. (TRDA) Common Stock on May 4, 2026, following the exercise of stock options. The filing also details multiple 10b5-1 sales made by Nathan Dowden in March 2026, including specific share counts and proceeds for each transaction. This SEC filing aims to ensure transparency regarding the sale of a significant number of shares, which can impact the stock's price.
TRDA (NASDAQ: TRDA) reports 25,907 RSUs to sell; insider sold March 2026
Entrada Therapeutics, Inc. (NASDAQ: TRDA) has filed a Form 144, indicating a proposed sale of 25,907 Restricted Stock Units (RSUs) with an award date of March 1, 2025. The filing also reveals two prior sales by an insider, Natarajan Sethuraman, in March 2026, totaling 7,577 and 3,898 common shares, generating proceeds of $89,078.24 and $45,442.49 respectively. The Form 144 is a regulatory document used for transparency when investors plan to sell a significant number of shares.
Entrada Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
Entrada Therapeutics Inc (TRDA) is projected to report a loss of $1.04 per share according to an earnings preview. This information comes from Reuters via TradingView News. The report suggests that analysts are anticipating a significant loss for the pharmaceutical company.
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Thursday
Entrada Therapeutics (TRDA) is expected to report its Q1 2026 earnings before market open on Thursday, May 7th, with analysts forecasting ($1.06) EPS and approximately $2.92 million in revenue. The company, which has a "Moderate Buy" consensus rating and a $19.00 target price, saw insider selling in March and has significant institutional ownership. Its previous quarter's earnings of ($0.94) per share beat estimates, though revenue was below expectations.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Analysts
Entrada Therapeutics (NASDAQ:TRDA) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $19.00. While the company's Q4 EPS beat estimates, revenue fell short, and recent insider selling has been noted, primarily from the CFO and COO. Institutions hold a significant 86.39% of the stock, while insiders hold 8.11%.
Entrada Therapeutics (NASDAQ: TRDA) details 2026 proxy and equity plan changes
Entrada Therapeutics (NASDAQ: TRDA) has detailed its 2026 proxy statement, outlining plans for its annual shareholder meeting on June 10, 2026. Shareholders will vote on electing two Class II directors, ratifying Ernst & Young LLP as the auditor, and approving amendments to the 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan. These amendments aim to include outstanding pre-funded warrants in the calculation of automatic share pool increases for both equity plans, aligning equity compensation capacity with the company's total capitalization.
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring a Potential 52.97% Upside in the Biotech Sector
Entrada Therapeutics, Inc. (TRDA) is presented as an intriguing investment opportunity in the biotechnology sector, focusing on innovative treatments for neuromuscular and inherited retinal diseases. Analysts express significant optimism, with eight "buy" ratings and a potential upside of up to 52.97% due to the company's pioneering Endosomal Escape Vehicle technology. Despite being in a pre-revenue stage with negative profitability metrics, the company's valuation points to anticipated future growth, making it a compelling, albeit risky, venture for long-term investors.
How Entrada Therapeutics Inc. (TRDA) Affects Rotational Strategy Timing
This article analyzes Entrada Therapeutics Inc. (TRDA) through the lens of quantitative research, highlighting strong underlying sentiment across all time horizons. It provides specific trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with entry zones, targets, and stop losses. The analysis also emphasizes significant risk-reward opportunities with a projected downside of 18.3% versus a minimal risk of 0.3%.
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN)
Two healthcare companies, Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN), recently received bullish sentiments from analysts. Oppenheimer reiterated a Buy rating on Entrada Therapeutics with a $23.00 price target, while LifeSci Capital maintained a Buy rating on Viridian Therapeutics with a $46.00 price target. Both companies show strong buy consensus ratings and significant upside potential according to TipRanks.
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN)
Analysts from Oppenheimer and LifeSci Capital have issued bullish sentiments on Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) respectively. Entrada Therapeutics received a reiterated Buy rating with a $23.00 price target from Oppenheimer, while Viridian Therapeutics maintained a Buy rating and a $46.00 price target from LifeSci Capital. Both companies currently hold a "Strong Buy" analyst consensus rating, indicating significant upside potential from current levels.
TRDA PE Ratio & Valuation, Is TRDA Overvalued
This article analyzes the valuation of Entrada Therapeutics Inc (TRDA), concluding that the stock is currently undervalued. Based on a forward P/S ratio of 16.07 compared to its five-year average of 158.93, the fair price is estimated to be between $22.95 and $31.22, making it undervalued by 42.69% from its current price of $13.15. The article also details other valuation metrics like P/B ratio, FCF yield, and comparisons to competitor averages.
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock By Investing.com
Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, sold 2,500 shares of TRDA common stock for $32,375 on April 1, 2026. This sale, conducted under a Rule 10b5-1 trading plan, leaves Wentworth with 119,010 shares. The transaction occurred while TRDA stock was near its 52-week high, and InvestingPro analysis suggests the stock is overvalued despite analysts' price targets of $19-21.
Entrada Therapeutics (TRDA) CFO sells 2,500 shares under 10b5-1 plan
Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, sold 2,500 shares of common stock at $12.95 per share through an open-market transaction. This sale was conducted under a pre-scheduled Rule 10b5-1 trading plan adopted on March 6, 2025. After the transaction, Wentworth directly holds 119,010 shares of the company.
